Biocon Announces Publication of Phase III Clinical Data Supporting Yesafili™ (Aflibercept Biosimilar)

What Happened ?

Key Details

Clinical Publication Highlights:

• Two independent peer-reviewed clinical studies have now been published.
• The first manuscript appeared in the British Journal of Ophthalmology on June 29, 2026.
• The second manuscript was published in Expert Opinion on Biological Therapy on May 18, 2026.
• Both studies are based on data generated from Biocon’s global Phase III INSIGHT trial.

20-Week Extension Study:

The extension study evaluated patients who either:

• Continued treatment with MYL-1701P, or
• Switched from reference aflibercept to MYL-1701P.

Key observations included:

• Comparable safety profile
• Comparable efficacy
• Comparable immunogenicity
• Maintenance of functional and anatomical outcomes throughout the extension period

Diabetic Macular Edema Subgroup Analysis:

The second publication evaluated multiple clinically relevant patient subgroups based on:

• Visual acuity
• Central subfield thickness
• Age
• Gender
• Race
• Geographic region
• Glycated hemoglobin
• Anti-drug antibody status
• Previous anti-VEGF therapy

Across these patient groups, MYL-1701P demonstrated:

• Comparable improvement in visual acuity
• Comparable reduction in retinal thickness
• Clinical equivalence with reference aflibercept

Regulatory Position:

Biocon highlighted that:

• Yesafili™ received U.S. FDA approval with interchangeable designation in May 2024.
• The therapy is indicated for:
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)

Investor Relevance:

• The announcement does not include any commercial launch update, revenue guidance or sales contribution.

Risk Analysis

Summary:

• While publication in leading peer-reviewed journals significantly strengthens the scientific foundation supporting Yesafili™, the announcement itself does not create an immediate financial impact.

Risk Points:

• Clinical validation does not automatically translate into commercial sales.
• Physician adoption will depend on treatment experience and prescribing behavior.
• Competition from branded biologics and other biosimilars remains significant.
• Pricing, reimbursement policies and healthcare access will influence market penetration.
• Future commercial performance remains subject to regulatory and market conditions.

Worst Case:

• If physician adoption or reimbursement progresses slower than expected, the strengthened clinical evidence may take longer to convert into meaningful revenue contribution despite positive scientific outcomes.

Risk Level: Medium

Company Commentary

Biocon management emphasized that the newly published studies represent an important milestone for the company’s ophthalmology biosimilar program.

Key management observations include:

• CEO & Managing Director Shreehas Tambe stated that the publications reinforce Biocon’s science-led strategy and support broader patient access to high-quality biosimilars.
• Chief Medical Officer Dr. Elena Wolff-Holz said the published evidence validates consistent clinical outcomes after switching from the reference biologic and confirms comparability across multiple patient populations.
• Management believes the growing clinical evidence base supports Yesafili™ as a reliable treatment option for diabetic macular edema.